Los Angeles, October 23, 2017 - Today, Stockwatchindex (SWI) announces that it has added three new promising picks to its Biotech "QuickPicks Portfolio". As it is typical for us, we are not headlining this with "1000% increase imminent tomorrow" but all our picks are always supported by solid SWI Research and the initial "BUY" recommendation by major Third Party Analysts. We let the continuing strong performance of our two portfolios "SWI QuickPicks" and "SWI Portfolio" over the last three years speak for itself.

BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter (OTC), and supplement applications in the health and wellness markets, including dermatology and women's health. To learn more about BioPharmX, visit  www.BioPharmX.com .

Closed at $0.24 on Friday

Analyst Recommendation is "Buy"

with a Price Target of $2.20

Valeritas Holdings, Inc. (VLRX) is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit  www.valeritas.com .

Closed at $2.12 on Friday

Analyst Recommendation is "Strong Buy"

with a Price Target of $12

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, the company established a broad drug discovery and development platform that has served as the foundation for continued efforts to bring new cancer therapies to patients in need. EXCEL discovered its lead compounds, cabozantinib and cobimetinib, and advanced them into clinical development before entering into partnerships with leading biopharmaceutical companies. With growing revenues from the three resulting commercialized products, EXEL is reinvesting in its business to maximize the potential of the product pipeline, which it intends to supplement with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer.

Closed at $27.17 on Friday

Third Party Analyst Recommendation is "Buy"

with a Price Target of $32.29

If you want to follow all other companies that we cover with more in depth research reports, go to our research site at www.swiresearch.com/report-index to download the reports,

or visit www.stockwatchindex.com for up to date news on the covered companies.

Please feel free to re-distribute the reports to your friends and colleagues.

Rainer Poertner - Chief Analyst

StockWatchIndex and SWI Research (SWI) are not registered investment advisers and the information provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. SWI has not been compensated for this report, but may hold or plan to acquire positions of every stock in this report for its portfolio and reserves the right to buy or sell positions at its sole discretion. The included information is subject to change without notice. Please visit  www.swiresearch.com/#!legal-ease/lmvw1   for a full text of our Disclaimer, Privacy policy and Terms of Use.